Incyte Corporation

Matthew S McCammant

Wenqing Yao

Xiaozhao Wang

Liangxing Wu

Zhiyong Yu

Le Zhao

Heeoon Han

Wenyu Zhu

Oleg Vechorkin

Alexander Sokolsky

Qinda Ye

Artem Shvartsbart

Chao Qi

Evan Styduhar

Bin Hu

Robert Swyka

Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Quinoline compounds as inhibitors of KRAS

The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.

Tricyclic heterocycles as FGFR inhibitors

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Fused pyrimidine derivatives as A2A/A2B inhibitors

Fused pyrimidine derivatives as A2A / A2B inhibitors

Growing community of inventors

Newark, DE, United States of America

Matthew S McCammant